Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mikhaeel, N. G.
Right arrow Articles by O'Doherty, M. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mikhaeel, N. G.
Right arrow Articles by O'Doherty, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:S147-S150, 2000
© 2000 European Society for Medical Oncology

Symposium Articles

18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas

N. G. Mikhaeel, A. R. Timothy, S. F. Hain and M. J. O'Doherty

Department of Clinical Oncology & Clinical PET Centre, St. Thomas' Hospital London, UK

Correspondence to: A. R. Timothy, MD Department of Clinical Oncology St. Thomas Hospital Lambeth Palace Road London SE1 7EH UK

Background: The problem of residual masses on post-treatment CT scans is a continuing dilemma for the oncologist treating malignant lymphomas. These masses may contain active disease or represent only necrotic tumour which continues to shrink without further treatment or post-treatment fibrosis which remains stable on continued follow-up. 18-FDG-PET offers a novel metabolic imaging modality, which can differentiate malignant from benign tissue on the basis of increased glycolytic activity.

Patients and methods: Thirty-two patients (15 with Hodgkin's disease (HD) and 17 with aggressive histology non-Hodgkin's lymphoma (NHL)) who had residual masses on their post-treatment CT scans underwent 18-FDG-PET. The post-treatment CT and PET scans were compared and the accuracy of the 18-FDG-PET in assessing residual masses was evaluated using clinical and pathological follow-up data.

Results: Nine patients had positive post-treatment 18-FDG-PET, eight (89%) of whom have relapsed. Twenty-three patients had negative post-treatment PET with only two relapses in this group. The 2 patients who relapsed had aggressive NHL while none of the 11 HD patients with negative PET relapsed. The median follow-up of patients in continued complete remission is 38 months.

Conclusions: 18-FDG-PET can differentiate between residual masses containing viable lymphoma where further treatment will be required to achieve cure and those representing ablated disease, where unnecessary treatment and additional morbidity may be avoided.

lymphoma, PET, remission assessment, residual masses


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
T. C. Kwee, R. M. Kwee, and R. A. J. Nievelstein
Imaging in staging of malignant lymphoma: a systematic review
Blood, January 15, 2008; 111(2): 504 - 516.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Jerusalem, Y. Beguin, M. F. Fassotte, T. Belhocine, R. Hustinx, P. Rigo, and G. Fillet
Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease
Ann. Onc., January 1, 2003; 14(1): 123 - 130.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.